NEW YORK, June 01, 2023 Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and. | June 1, 2023
02.05.2023 - Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ETNEW YORK, May 02, 2023 (GLOBE NEWSWIRE) - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing .
Intellectual Property Portfolio for the Treatment of Hypertension Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing. | May 1, 2023
Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. | April 25, 2023
25.04.2023 - NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and .